<DOC>
	<DOCNO>NCT00890591</DOCNO>
	<brief_summary>In patient naive treatment 2-week washout period patient whose treatment ineffective , use olmesartan assess 4-phase treatment scheme : monotherapy , addition hydrochlorothiazide ( 2 phase ) , addition amlodipine .</brief_summary>
	<brief_title>Efficacy Safety Olmesartan Medoxomil Stage 1 2 Essential Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Olmesartan</mesh_term>
	<mesh_term>Olmesartan Medoxomil</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<mesh_term>Angiotensin II Type 1 Receptor Blockers</mesh_term>
	<criteria>Stage 1 2 hypertension without treatment least 2 week Women risk become pregnant Study participation could result risk health subject Cardiovascular disease Secondary hypertension stage 3 hypertension Myocardial infarction within last 6 month Congestive heart failure Pulmonary edema Valvular alteration rheumatic cardiopathy Clinically relevant conduction disorder significant arrhythmias Alcohol illicit drug use Medication abuse Pregnant nursing woman</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2009</verification_date>
	<keyword>hypertension</keyword>
	<keyword>angiotensin II type 1 receptor blocker</keyword>
	<keyword>olmesartan</keyword>
</DOC>